Loading cancer entity…
Loading cancer entity…
Clinical trials
3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01085214 | AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Aug 19, 2015 | clinicaltrials |
| NCT02221479 | Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma | completed | Phase 2 | 14 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 4, 2015 | clinicaltrials |
| NCT00131261 | Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma | completed | Phase 2 | 25 | Valerio TherapeuticsINDUSTRY | 4 | Jul 8, 2015 | clinicaltrials |
| NCT00083382 | Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide | completed | Phase 2 | 83 | University of ArkansasOTHER | 1 | Jun 24, 2015 | clinicaltrials |
| NCT01531998 | Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT00201695 | Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma | completed | Phase 2 | 12 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 10, 2015 | clinicaltrials |
| NCT02467010 | Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance(REMM) | completed | Phase 2 | 73 | University Medical Center GroningenOTHER | 1 | Jun 9, 2015 | clinicaltrials |
| NCT00998049 | Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant | completed | Phase 2 | 40 | Mayo ClinicOTHER | 1 | May 14, 2015 | clinicaltrials |
| NCT00778752 | Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma | completed | Phase 1 / Phase 2 | 24 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT01160484 | Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 40 | OncotherapeuticsINDUSTRY | 1 | May 4, 2015 | clinicaltrials |
| NCT00066638 | FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2015 | clinicaltrials |
| NCT00002849 | S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis | completed | Phase 2 | 93 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00809276 | Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY | completed | Phase 1 / Phase 2 | 92 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 16, 2015 | clinicaltrials |
| NCT01849848 | Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 17 | SymBio PharmaceuticalsINDUSTRY | 1 | Feb 6, 2015 | clinicaltrials |
| NCT00908232 | Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD(SEQUENTIAL) | completed | Phase 2 | 163 | Janssen-Cilag International NVINDUSTRY | 10 | Jan 15, 2015 | clinicaltrials |
| NCT00833560 | A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy | completed | Phase 2 | 401 | Janssen-Cilag G.m.b.HINDUSTRY | 1 | Nov 21, 2014 | clinicaltrials |
| NCT00911859 | A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients | completed | Phase 2 | 118 | Janssen Research & Development, LLCINDUSTRY | 11 | Nov 18, 2014 | clinicaltrials |
| NCT00564200 | MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning(MINIALO-VELCAD) | completed | Phase 2 | 30 | PETHEMA FoundationOTHER | 1 | Oct 28, 2014 | clinicaltrials |
| NCT00505895 | FM 140 vs FM100 Study in Patients With Multiple Myeloma | completed | Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 17, 2014 | clinicaltrials |
| NCT01095757 | Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection | completed | Phase 2 | 45 | Emory UniversityOTHER | 1 | Sep 29, 2014 | clinicaltrials |
| NCT00691704 | Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy | completed | Phase 2 | 18 | Cristina GasparettoOTHER | 1 | Aug 19, 2014 | clinicaltrials |
| NCT00972959 | Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy | completed | Phase 2 | 17 | University of AthensOTHER | 1 | Aug 5, 2014 | clinicaltrials |
| NCT00586014 | High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma | completed | Phase 2 | 91 | Duke UniversityOTHER | 0 | Jul 8, 2014 | clinicaltrials |
| NCT01096342 | Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 2 | Jun 18, 2014 | clinicaltrials |
| NCT01283776 | Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation(OCTET-CY) | completed | Phase 2 | 11 | University of CologneOTHER | 1 | Jun 10, 2014 | clinicaltrials |
| NCT00580034 | Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath | completed | Phase 2 | 176 | David Rizzieri, MDOTHER | 1 | Jun 3, 2014 | clinicaltrials |
| NCT00075881 | Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00597714 | Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant | completed | Phase 2 | 264 | David Rizzieri, MDOTHER | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00514137 | Sunitinib in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00872521 | A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma | completed | Phase 2 | 107 | Janssen-Cilag Pty LtdINDUSTRY | 1 | May 16, 2014 | clinicaltrials |
| NCT00402181 | An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 53 | Centocor, Inc.INDUSTRY | 2 | May 14, 2014 | clinicaltrials |
| NCT00431769 | An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma | completed | Phase 2 | 130 | Janssen-Cilag International NVINDUSTRY | 8 | May 12, 2014 | clinicaltrials |
| NCT00743288 | Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | OncotherapeuticsINDUSTRY | 1 | May 8, 2014 | clinicaltrials |
| NCT00901225 | Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant | completed | Phase 2 | 21 | Duke UniversityOTHER | 1 | May 7, 2014 | clinicaltrials |
| NCT01105403 | Exploratory Study on POL6326 in Stem Cell Mobilization | completed | Phase 2 | 21 | Polyphor Ltd.INDUSTRY | 1 | Apr 23, 2014 | clinicaltrials |
| NCT01220375 | PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma(PAV) | completed | Phase 2 | 44 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Apr 17, 2014 | clinicaltrials |
| NCT00847639 | Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma(07-REV) | completed | Phase 2 | 30 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Apr 4, 2014 | clinicaltrials |
| NCT00322387 | Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients | completed | Phase 2 | 40 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00322491 | Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients | completed | Phase 2 | 49 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00322842 | Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients | completed | Phase 2 | 35 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00396266 | AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF | completed | Phase 2 | 22 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 7, 2014 | clinicaltrials |
| NCT00970021 | Agaricus Blazei Murill in Patients With Multiple Myeloma | completed | Phase 2 | 39 | Ullevaal University HospitalOTHER | 1 | Feb 25, 2014 | clinicaltrials |
| NCT00665314 | Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM). | completed | Phase 2 | 5 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Feb 11, 2014 | clinicaltrials |
| NCT00750815 | Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 58 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 20, 2014 | clinicaltrials |
| NCT00617591 | Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM) | completed | Phase 2 | 57 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 17, 2014 | clinicaltrials |
| NCT00205751 | Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy | completed | Phase 2 / Phase 3 | 350 | Austrian Forum Against CancerOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT01168804 | Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma(BBD) | completed | Phase 2 | 79 | Austrian Forum Against CancerOTHER | 2 | Nov 25, 2013 | clinicaltrials |
| NCT00483262 | Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 63 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 11, 2013 | clinicaltrials |
| NCT01037517 | Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization | completed | Phase 2 | 52 | CancerCare ManitobaOTHER | 1 | Oct 31, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Aug 19, 2015source: clinicaltrials